Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicolas Marsheh

Internal Medicine Sterling Heights, MI Medical Doctor

NPI 1962423657 CMS profile 224384

43184 Dequindre Rd Ste 202, Sterling Heights, MI 48314

Open in the dashboard

General payments

$9,870

484 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicolas Marsheh of Sterling Heights, MI is reported in the CMS Open Payments database as having received $9,870 across 484 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,726 82
2024 General $1,380 70
2023 General $1,290 59
2022 General $1,606 74
2021 General $1,501 73
2020 General $1,046 58
2019 General $1,320 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicolas Marsheh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Nicolas Marsheh were reported at $1,726. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Nicolas Marsheh Internal Medicine median Middle half National median
2019 $1,320 $159 $48–$570 $163
2020 $1,046 $119 $33–$402 $114
2021 $1,501 $135 $37–$521 $132
2022 $1,606 $141 $42–$496 $149
2023 $1,290 $149 $45–$519 $160
2024 $1,380 $154 $47–$537 $164
2025 $1,726 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,676 72 payments
  2. GlaxoSmithKline, LLC. $1,213 50 payments
  3. Pfizer Inc. $1,141 71 payments
  4. Novo Nordisk Inc $666 30 payments
  5. AbbVie, Inc. $648 33 payments
  6. Lilly USA, LLC $624 27 payments
  7. Esperion Therapeutics, Inc. $463 24 payments
  8. AstraZeneca Pharmaceuticals LP $442 24 payments
  9. Janssen Pharmaceuticals, Inc $390 21 payments
  10. Novartis Pharmaceuticals Corporation $295 19 payments
  11. Other $2,313 113 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,870 484 payments
Products named General payments · program years 2019–2025
  1. Repatha $886 40 payments
  2. TRELEGY ELLIPTA $758 37 payments
  3. Otezla $648 37 payments
  4. COLOGUARD $532 34 payments
  5. Ozempic $517 26 payments
  6. NEXLETOL $463 24 payments
  7. RYBELSUS $460 24 payments
  8. VRAYLAR $440 22 payments
  9. MOUNJARO $380 13 payments
  10. XARELTO $371 20 payments
  11. Other $7,584 412 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

5,340

Median for Internal Medicine: 777

Drug cost

$539,870

Median for Internal Medicine: $73,373

Branded share of claims

23.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 89 $79,483
Eliquis Apixaban Brand 66 $69,738
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 77 $68,847
Ozempic Semaglutide Brand 59 $62,227
Rybelsus Semaglutide Brand 28 $40,921
Januvia Sitagliptin Phosphate Brand 31 $33,022
Farxiga Dapagliflozin Propanediol Brand 24 $18,678
Myrbetriq Mirabegron Brand 24 $16,903
Nexlizet Bempedoic Acid/Ezetimibe Brand 27 $14,357
Repatha Sureclick Evolocumab Brand 20 $13,942

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 96 billing codes

Paid by Medicare

$311,764

Of which drugs: $3,419

Medicare patients

689

Average age 74

Services billed

7,169

365 women, 324 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 49%
Ischemic heart disease 48%
Chronic kidney disease 45%
Heart failure 41%
COPD 38%
Atrial fibrillation 35%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 37 37 $3,027
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 37 77 $65
Injection, methylprednisolone acetate, 1 mg J1010 Office 13 541 $50
Injection, ketorolac tromethamine, per 15 mg J1885 Office 13 72 $33

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $233
$233 — —
MOUNJARO
  • Lilly USA, LLC $159
$159 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $133
$133 — —
Repatha
  • Amgen Inc. $83
$83 33 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $72
$72 77 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

484 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record